China Pharma Holdings (CPHI) Debt to Equity (2016 - 2025)
China Pharma Holdings (CPHI) has disclosed Debt to Equity for 16 consecutive years, with $0.17 as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Debt to Equity fell 55.05% year-over-year to $0.17, compared with a TTM value of $0.17 through Sep 2025, down 55.05%, and an annual FY2024 reading of $0.33, down 4.15% over the prior year.
- Debt to Equity was $0.17 for Q3 2025 at China Pharma Holdings, down from $0.42 in the prior quarter.
- Across five years, Debt to Equity topped out at $1.62 in Q3 2022 and bottomed at $0.17 in Q3 2025.
- Average Debt to Equity over 5 years is $0.54, with a median of $0.42 recorded in 2025.
- The sharpest move saw Debt to Equity soared 156.51% in 2022, then plummeted 75.68% in 2023.
- Year by year, Debt to Equity stood at $0.72 in 2021, then decreased by 20.9% to $0.57 in 2022, then plummeted by 39.98% to $0.34 in 2023, then decreased by 4.15% to $0.33 in 2024, then tumbled by 48.07% to $0.17 in 2025.
- Business Quant data shows Debt to Equity for CPHI at $0.17 in Q3 2025, $0.42 in Q2 2025, and $0.37 in Q1 2025.